Organoidsciences Ltd
476040
Company Profile
Business description
Organoidsciences Ltd is a three-dimensional cell structure created by self-organization. It has two products, ATORM, which is a medicine applied to various diseases and was developed using organoids derived from tissues such as intestines and salivary glands. ODISEI, an organoid-based new material evaluation solution, is an evaluation service for predicting the effects of various new materials, such as new drugs, foods, and cosmetics, when applied to the human body, and was developed using organoids for tumors, viruses, intestines, and skin.
Contact
338 Pangyo-ro
6th floor, Bundang-gu
Gyeonggi-do
Seongnam-si
KORT: +82 27072024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
86
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,153.30 | 6.80 | -0.07% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,072.24 | 583.65 | 1.20% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,592.51 | 7.45 | 0.03% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,760.85 | 986.21 | 1.87% |
| NZX 50 Index | 13,514.73 | 59.20 | -0.44% |
| S&P 500 | 6,873.77 | 76.91 | 1.13% |
| S&P/ASX 200 | 8,829.80 | 6.10 | -0.07% |
| SSE Composite Index | 4,123.91 | 6.97 | 0.17% |